This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Craig McDonald, MD, University of California, Davis
Cardero Therapeutics, Inc.
Information provided by (Responsible Party):
Craig McDonald, MD, University of California, Davis Identifier:
First received: May 9, 2013
Last updated: March 10, 2017
Last verified: March 2017
(-)-Epicatechin will be evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients.

Condition Intervention Phase
Becker Muscular Dystrophy Drug: (-)-epicatechin Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.

Resource links provided by NLM:

Further study details as provided by Craig McDonald, MD, University of California, Davis:

Primary Outcome Measures:
  • Muscle Function [ Time Frame: 8 weeks ]
  • Muscle Stength [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • -(-)Epicatechin Pharmacokinetics [ Time Frame: 8 Weeks ]
    Standard clinical safety panel including: hematologic, hepatologic, renal and metabolic profiles

Other Outcome Measures:
  • Normalization of Muscle Stucture [ Time Frame: 8 weeks ]
    Evaluation by histology, Western Blot, immunostain and electron microscopy

Estimated Enrollment: 10
Study Start Date: May 2013
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment with Epicatechin
Purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
Drug: (-)-epicatechin
purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
Other Name: dietary supplement

Detailed Description:

This is a proof-of-concept phase 1/2a pilot and endpoint development study that is designed to provide initial evidence of biological activity of (-)-epicatechin. Primary endpoints include initial assessment of tissue-specific evidence of efficacy from muscle biopsy samples. Secondary endpoints include measures of strength and physical function, and safety and adverse event data. Pilot endpoints include assessment of mRNA and miRNA peripheral blood profiles and validation of non-invasive near-infrared spectroscopy (NIRS) muscle perfusion studies during exercise and a recumbent cycle exercise test that may be employed as endpoints in future clinical trials.

This single center open-label pilot study will enroll 10 adults with genetically-confirmed Becker muscular dystrophy, who will receive the purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks. After screening visits, participants will be enrolled in the study if they meet all inclusion criteria. They will be evaluated at baseline and at screening, day 1, and weeks 1, 2, 4 and 8.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male
  • Age 18 years to 60 years
  • Average to low daily physical activity
  • Ability to ambulate for 75 meters without assistive devices
  • Diagnosis of BMD confirmed by at least one the following:

    • Dystrophin immunofluorescence and/or immunoblot showing partial dystrophin deficiency, and clinical picture consistent with typical BMD, or
    • Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'in-frame', and clinical picture consistent with typical BMD, or
    • Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with BMD, with a typical clinical picture of BMD, or
    • Positive family history of BMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of BMD.
  • Nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility have been discontinued at least 2 weeks prior to screening (daily multivitamin use is acceptable).
  • Hematology profile within normal range
  • Baseline laboratory safety chemistry profile within normal range
  • No plan to change exercise regimen during study participation

Exclusion Criteria:

  • Currently enrolled in another treatment clinical trial.
  • History of significant concomitant illness or significant impairment of renal or hepatic function.
  • Use of regular daily aspirin or other medication with antiplatelet effects within 3 weeks of first dose of study medication.
  • Regular participation in vigorous exercise.
  • Symptomatic heart failure with cardiac ejection fraction <25%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01856868

Contact: Erica Goude, BA CCRP 916-734-0968

United States, California
University of California, Davis Recruiting
Sacramento, California, United States, 95817
Contact: Erica Goude, BA CCRP    916-734-0968   
Principal Investigator: Craig M McDonald, MD         
Sub-Investigator: Erik K Henricson, MPH         
Sub-Investigator: Richard T Abresch, MS         
Sub-Investigator: Frank Sharp, MD         
Sub-Investigator: Glenn Jickling, MD         
Sub-Investigator: Bjorn E Oskarsson, MD         
Sponsors and Collaborators
Craig McDonald, MD
Cardero Therapeutics, Inc.
Principal Investigator: Craig M McDonald, MD University of California, Davis
Study Director: Erik K Henricson, MPH University of California, Davis
  More Information

Additional Information:
Responsible Party: Craig McDonald, MD, Professor and Chairman, Department of Physical Medicine and Rehabilitation, University of California, Davis Identifier: NCT01856868     History of Changes
Other Study ID Numbers: 454352
Study First Received: May 9, 2013
Last Updated: March 10, 2017

Keywords provided by Craig McDonald, MD, University of California, Davis:
Becker muscular dystrophy
clinical trial
neuromuscular disease

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked processed this record on September 21, 2017